US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Champion Industries, Inc.

0.0001

+0.0000

Volume:- -

Turnover:- -

Market Cap:5.59

PE:0.00

High:0.0001

Open:0.0001

Low:0.0001

Close:0.0001

Loading ...

Overview Company News Filings

Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug

Bristol Myers receives positive CHMP opinion for repotrectinib

Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug

CHMP issues positive recommendation for approval of lecanemab in the EU

Biogen, Eisai Win CHMP Backing of Leqembi Alzheimer's Drug

Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’s disease

Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights

BUZZ-Apellis Pharmaceuticals falls on wider-than-expected Q3 loss

Press Release: Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

Pharming Group reports third quarter 2024 financial results and provides business update

AstraZeneca Receives CHMP's Approval for Wainzua in Europe

Novartis Gets CHMP Recommendation for Kisqali in Broader Population

NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B

BeiGene receives positive CHMP opinions for tevimbra in gastric cancers

Ionis Pharmaceuticals announces CHMP recommends approval for Wainzua

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer

Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug

PTC Therapeutics: CHMP Again Recommends Against Translarna Renewal

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHMP/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"Champion Industries, Inc.","latestPrice":0.0001,"timestamp":1744920000000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"Market Closed","change":0,"latestTime":"04-17 16:00:00 EDT Delay","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":2.7777835648268714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"volumeRatio":2.7777835648268714,"shares":55857,"dividePrice":0,"high":0.0001,"amplitude":0,"preClose":0.0001,"low":0.0001,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.0001,"institutionHeld":0,"latestPrice":0.0001,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.0001,"prevYearClose":0.0001,"prevWeekClose":0.0001,"prevMonthClose":0.0001,"prevQuarterClose":0.0001,"fiveDayClose":0.0001,"twentyDayClose":0.0001,"sixtyDayClose":0.0001},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2483531320","title":"Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2483531320","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483531320?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:34","pubTimestamp":1731674040,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.The Princeton, N.J., biopharmaceutical company said the recommendation cover Augtyro as a treatment for adults with ROS1-positive advanced non-small cell lung cancer and for certain patients 12 and older with advanced solid tumors expressing a NTRK gene fusion.The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected in January.Bristol Myers said Augtyro, if approved, has the potential to be a best-in-class treatment for patients with advanced ROS1-positive non-small cell lung cancer in the European Union.The U.S. Food and Drug Administration last year approved Augtyro for adults with ROS1-positive non-small cell lung cancer and earlier this year gave a green light to the drug in patients with NTRK-positive solid tumors.Bristo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU2242652126.USD","LU0306806265.USD","CHMP","LU0456855351.SGD","LU1989771016.USD","BK4559","LU2360032135.SGD","LU2133065610.SGD","MYE","LU1093756325.SGD","LU1670710661.SGD","LU0225771236.USD","LU0306807586.USD","LU0321505868.SGD","BK4126","LU0321505439.SGD","LU0882574055.USD","IE0009355771.USD","LU1261432733.SGD","LU0237698245.USD","LU1093756168.USD","LU1074936037.SGD","IE00BJT1NW94.SGD","LU1032466523.USD","LU0985481810.HKD","BK4588","LU0114720955.EUR","LU1670711123.USD","BK4007","BK4087","LU1718418525.SGD","IE00B2B36J28.USD","LU1291159041.SGD","LU2125154935.USD","LU1670710588.SGD","LU0868494617.USD","IE00BFTCPJ56.SGD","LU0061475181.USD","LU0225284248.USD","LU1571399168.USD","BK4532","BMY","IE00BJJMRZ35.SGD","IE0002141913.USD","LU1585245621.USD","LU2125154778.USD","BK4534","IE00BSNM7G36.USD","BK4585"],"gpt_icon":0},{"id":"2483275923","title":"Bristol Myers receives positive CHMP opinion for repotrectinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2483275923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483275923?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:06","pubTimestamp":1731672418,"startTime":"0","endTime":"0","summary":"Bristol Myers (BMY) Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended appro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bristol-myers-receives-positive-chmp-opinion-for-repotrectinib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bristol-myers-receives-positive-chmp-opinion-for-repotrectinib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0306806265.USD","LU0985481810.HKD","IE00BSNM7G36.USD","LU1074936037.SGD","LU1718418525.SGD","BMY","IE0002141913.USD","IE00B2B36J28.USD","BK4581","LU1585245621.USD","LU2360032135.SGD","LU0456855351.SGD","LU1291159041.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU1032466523.USD","LU0225771236.USD","CHMP","MYE","LU1430594728.SGD","LU0882574055.USD","BK4126","LU0321505439.SGD","LU0306807586.USD","LU1670710588.SGD","LU1261432733.SGD","LU0868494617.USD","BK4007","BK4559","BK4532","BK4087","LU1093756168.USD","LU1670711123.USD","LU1670711040.USD","BK4588","LU1093756325.SGD","LU1571399168.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU0061475181.USD","LU0237698245.USD","LU2133065610.SGD","LU1670710661.SGD","LU2242652126.USD","LU2125154778.USD","LU2125154935.USD","BK4585","LU2242646821.SGD","LU1989771016.USD","LU0225284248.USD"],"gpt_icon":0},{"id":"2483380416","title":"Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2483380416","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483380416?lang=en_us&edition=fundamental","pubTime":"2024-11-15 02:21","pubTimestamp":1731608460,"startTime":"0","endTime":"0","summary":"EMA issues positive opinion on Leqembi, albeit for a limited patient group. Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai - reversing an earlier decision not to approve the drug.The European Medicines Agency had issued a negative opinion on the drug, called Leqembi, in July, citing a side effect that involves swelling and potential bleeding in the brain.\"After re-examining its initial opinion, EMA's human-medicines committee  has recommended granting a marketing authorization to Leqembi  for treating mild cognitive impairment  or mild dementia due to Alzheimer's disease,\" the EMA said in a statement.But the drug is only being recommended for patients who are not carriers of Apoe4, a protein involved in the metabolism of fats in humans that is known to be a risk factor in Alzheimer's.Eisai had requested that the EMA revisit its negative opinion","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","BK4581","IE00B894F039.SGD","BK4585","ESAIY","LU0234570918.USD","BK4533","BK4532","LU0109394709.USD","LU0889565916.HKD","BK4139","BK4007","CHMP","IE00B19Z9Z06.USD","BIIB","BK4588","BK4087","LU0320765992.SGD","XBI"],"gpt_icon":0},{"id":"2483381961","title":"CHMP issues positive recommendation for approval of lecanemab in the EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2483381961","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483381961?lang=en_us&edition=fundamental","pubTime":"2024-11-15 01:00","pubTimestamp":1731603600,"startTime":"0","endTime":"0","summary":"STOCKHOLM, Nov. 14, 2024 /PRNewswire/ -- BioArctic AB   today announces that EMA's Committee for Medicinal Products for Human Use  has issued a positive recommendation regarding BioArctic's partner Eisai's marketing authorization application  for lecanemab as treatment of Alzheimer's disease. The recommendation applies to the treatment of early Alzheimer's disease in adult patients that are apolipoprotein E ε4  heterozygotes or non-carriers.The CHMP recommendation for the European Commission to approve lecanemab follows Eisai's request for a re-examination of the CHMP's earlier negative recommendation. A decision from the European Commission is expected within 67 days.Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, United Arab Emirates and Great Britain for the treatment of MCI due to AD and mild AD dementia. Lecanemab's approvals in these countries, as well as the CHMP's opinion, were primarily based on Phase 3 data from Eisai's global Clarity AD clini","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hdJh9LqLvU6kukp1u7GyLg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/d71fdf0a9a58ad61dcb8c489cc42322f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hdJh9LqLvU6kukp1u7GyLg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/d71fdf0a9a58ad61dcb8c489cc42322f"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/chmp-issues-positive-recommendation-approval-170000789.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chmp-issues-positive-recommendation-approval-170000789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4156","CHMP","MCI","BK4588","MAA","BRCTF","BK4087","BK4215","BK4585"],"gpt_icon":0},{"id":"2483816233","title":"Biogen, Eisai Win CHMP Backing of Leqembi Alzheimer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2483816233","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483816233?lang=en_us&edition=fundamental","pubTime":"2024-11-15 00:59","pubTimestamp":1731603540,"startTime":"0","endTime":"0","summary":"A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai.The companies on Thursday said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion on the drug after a re-examination of its earlier negative stance.The CHMP in July recommended against approval of Leqembi, citing safety and efficacy issues, but Biogen and Eisai asked the panel to take another look.The companies said the European Commission which generally follows the CHMP's advice, is expected to make a final decision within 67 days. The U.S. Food and Drug Administration last year approved Leqembi, which also is approved in the U.K., Japan, China and several other countries.Japan's Eisai serves as the lead for Leqembi's development and regulatory submissions worldwide and co-commercializes the drug with Cambridge, Mass., biotechnology company Biogen.The drug generated third-quarter sales of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B894F039.SGD","BK4139","LU0234570918.USD","BK4532","CHMP","LU0109394709.USD","LU0320765992.SGD","BK4087","BK4588","BK4533","LU0889565916.HKD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BIIB"],"gpt_icon":0},{"id":"2483324389","title":"Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2483324389","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483324389?lang=en_us&edition=fundamental","pubTime":"2024-11-15 00:32","pubTimestamp":1731601952,"startTime":"0","endTime":"0","summary":"Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eisai-receives-positive-chmp-opinion-for-lecanemab-in-early-alzheimers-disease?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eisai-receives-positive-chmp-opinion-for-lecanemab-in-early-alzheimers-disease?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4087","LU0234570918.USD","BK4533","IE00B19Z9P08.USD","LU0320765992.SGD","LU0109394709.USD","CHMP","BK4532","BK4139","IE00B894F039.SGD","BK4585","BK4007","BK4588","IE00B19Z9Z06.USD","BIIB","ESAIY","LU0889565916.HKD"],"gpt_icon":0},{"id":"2481903507","title":"Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2481903507","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481903507?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980800,"startTime":"0","endTime":"0","summary":"Achieved $28.2 million in RYTELO  net product revenue in first full quarter of sales. Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt. FOSTER CITY, Calif., November 07, 2024----Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2024 and recent business highlights.Strong execution in the first full quarter of U.S. launch, with net product revenue for RYTELO  of $28.2 million in the third quarter of 2024.New data to be presented at upcoming American Society for Hematology  Annua","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zZLo_DXqApn6_1miYjGswg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/42a99b4bc39a17084482402aa4c47f6e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zZLo_DXqApn6_1miYjGswg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/42a99b4bc39a17084482402aa4c47f6e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-reports-third-quarter-120000278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4087","BK4563","BK4585","ASH","BK4539","MAA","CHMP","BK4215","MF","OS","BK4113","GERN","BK4097","LU2463526074.USD","BK4526","BK4109","BK4588"],"gpt_icon":0},{"id":"2481688872","title":"BUZZ-Apellis Pharmaceuticals falls on wider-than-expected Q3 loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2481688872","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481688872?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:42","pubTimestamp":1730817746,"startTime":"0","endTime":"0","summary":"** Shares of biopharmaceutical firm Apellis Pharmaceuticals  fall 8.9% to $26.02   ** APLS opens at near three-month low   ** Co reports wider-than-expected loss in Q3        ** Q3 loss at 46 cents/shr vs. estimates of loss of 30 cents/shr - LSEG    **  Co reported Q3 rev of $196.8 mln vs. estimates of $200.35 mln - LSEG    ** APLS's SYFOVRE injection, which treats a macular degeneration disorder called geographic atrophy  received a negative opinion from the Committee for Medicinal Products for Human Use  in September   ** SYFOVRE net selling price declined relative to previous quarters due to an increase in gross-to-net adjustments - APLS   ** Co also expect regulatory decisions in the U.K., Switzerland, Canada and Australia in early 2025 for SYFORVE   ** 15 of 21 analysts that cover APLS rate the stock \"buy\" or higher, 6 \"hold\", median PT is $68 - LSEG    ** As of last close, stock down ~52% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4585","CHMP","LU1093756168.USD","BK4588","BK4139","LU1093756325.SGD","BK4087","APLS"],"gpt_icon":0},{"id":"2480212307","title":"Press Release: Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2480212307","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480212307?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023. JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025. French health authority approved pre-marketing early reimbursed access for B-VEC in France under the Accès Précoce  program; AP1 program for DEB patients access expected to start in 4Q 2024. Advancing Jeune Aesthetics' KB301 to Phase 2 after positive results in Phase 1. Clinical updates on AATD and oncology program before end of year. Strong balance sheet, ending the quarter with $694.2 million in cash and investments","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CF","BK4232","KRYS","BK4022","CHMP","BK4093","BK4588","MAA","BK4139","R","BK4585","BK4087","BK4215"],"gpt_icon":1},{"id":"2479704889","title":"Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2479704889","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479704889?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372400,"startTime":"0","endTime":"0","summary":"Rezdiffra  coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy. Completed enrollment of clinical outcomes study of Rezdiffra in patients with compensated NASH/MASH cirrhosis. Reports cash, cash equivalents, restricted cash and marketable securities of $1.0 billion at September 30, 2024. CONSHOHOCKEN, Pa., Oct. 31, 2024  -- Madrigal Pharmaceuticals, Inc. , a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis /metabolic dysfunction-associated steatohepatitis , today reports third-quarter 2024 financial results and provides corporate updates.In October, the Company announced that it completed enrollment in its MAESTRO-NASH OUTCOMES trial evaluating Rezdiffra for the treatment of patients with compensated NASH cirrhosis. Positive results from this study could result in Rezdiffra becoming the first medicine approved for patients with compensated cir","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7N3MAzczZuGCZhLcgXi2IQ--~B/aD03Nzt3PTM2MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4569c96927163aa87c649d3fe2a4b04d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7N3MAzczZuGCZhLcgXi2IQ--~B/aD03Nzt3PTM2MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4569c96927163aa87c649d3fe2a4b04d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/madrigal-pharmaceuticals-reports-third-quarter-110000847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","CHMP","BK4585","MDGL","MAA","BK4215","BK4087","BK4139"],"gpt_icon":0},{"id":"2479477296","title":"Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2479477296","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479477296?lang=en_us&edition=fundamental","pubTime":"2024-10-29 18:45","pubTimestamp":1730198700,"startTime":"0","endTime":"0","summary":"Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portfolio. Raises Full-Year 2024 Revenue Guidance to a Range of $61.0 to $64.0 Billion and Raises Adjusted Diluted EPS Guidance to a Range of $2.75 to $2.95. Third-Quarter 2024 Revenues of $17.7 Billion, Representing 32% Year-over-Year Operational Growth. Excluding Contributions from Paxlovid and Comirnaty, Revenues Grew 14% Operationally. Third-Quarter 2024 Reported Diluted EPS of $0.78 and Adjusted Diluted EPS of $1.06. On Track to Deliver Net Cost Savings of At Least $5.5 Billion from Previously Announced Cost Reduction Initiatives. At Least $4 Billion Anticipated by End of 2024 from Cost Realignment Program. NEW YORK, October 29, 2024----Pfizer Inc.  reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance for both Revenues and Adjusted diluted EPS.The third-quarter 2024 earnings presentation and accompanying prepared remarks ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CGtTsi1D8iMV8CVC6QtwAQ--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7ed0ef10cbffe892673393ced4c1205e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CGtTsi1D8iMV8CVC6QtwAQ--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7ed0ef10cbffe892673393ced4c1205e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b7ab36b62447dc898b2aab8b1c786e03","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-strong-third-quarter-104500192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FIX","SG9999002232.USD","BK4551","LU0321505868.SGD","LU1023059063.AUD","PFE","BK4585","EC","BK4139","LU1057294990.SGD","SG9999002224.SGD","BK4007","LU0058720904.USD","SCD","BNTX","BK4581","LU0306807586.USD","BK4535","SG9999011175.SGD","BK4568","LU1066051498.USD","BK4533","LU0321505439.SGD","LU0054578231.USD","LU0122379950.USD","LU0225771236.USD","LU0306806265.USD","BK4592","IE00BBT3K403.USD","SG9999001176.SGD","LU1894683264.USD","ESG","LU0053671581.USD","LU0170899867.USD","LU0985481810.HKD","SG9999001176.USD","SGXZ57979304.SGD","OS","BK4097","IE0002270589.USD","LU1883839398.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU0225284248.USD","CHMP","LU0234572021.USD","BK4588","CDC","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2477084523","title":"Pharming Group reports third quarter 2024 financial results and provides business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2477084523","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477084523?lang=en_us&edition=fundamental","pubTime":"2024-10-24 13:00","pubTimestamp":1729746000,"startTime":"0","endTime":"0","summary":"Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST and Joenja revenue growthRUCONEST third quarter revenue i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/24/2968335/0/en/Pharming-Group-reports-third-quarter-2024-financial-results-and-provides-business-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4229","BK4087","BK4195","NICE","IE00BFMHRM44.USD","AGM","PHAR","BK4566","CHMP","BK4139"],"gpt_icon":0},{"id":"2477364128","title":"AstraZeneca Receives CHMP's Approval for Wainzua in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2477364128","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477364128?lang=en_us&edition=fundamental","pubTime":"2024-10-23 00:51","pubTimestamp":1729615860,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use  has recommended approval for their drug Wainzua  for treating hereditary transthyretin-mediated amyloidosis, commonly called hATTR-PN or ATTRv-PN.If the European Commission approves Wainzua, it will become the only medicine approved for treating ATTRv-PN that can be self-administered monthly via an auto-injector in the European Union.Wainzua was approved by the name of Wainua in the United States in December last year. The drug was commercially launched in the United States in the first quarter of 2024.ATTRv-PN is a debilitating disease, which leads to peripheral nerve damage and affects an estimated 40,000 people worldwide. It can cause motor disability within five years of diagnosis, which can become fatal if not treated properly within a decade.Year to date, shares of AstraZeneca have increased 15% compared with the industry’s rally of 20.5%.Year to date, shares of Ionis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-receives-chmps-approval-wainzua-165100298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IONS","LU2456880835.USD","LU2462157665.USD","LU0889565916.HKD","BK4539","BK4588","LU2417539215.USD","BK4568","ANIP","LU2236285917.USD","AZN","BK4087","LU0109394709.USD","BK4585","CHMP","ELEV","BK4007","LU0320765992.SGD","LU1829250122.USD","BK4139"],"gpt_icon":0},{"id":"2477681350","title":"Novartis Gets CHMP Recommendation for Kisqali in Broader Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2477681350","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477681350?lang=en_us&edition=fundamental","pubTime":"2024-10-22 01:51","pubTimestamp":1729533060,"startTime":"0","endTime":"0","summary":"Novartis NVS announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency  recommended granting approval to the breast cancer drug Kisqali  for a broader patient population.The CHMP adopted a positive opinion for the marketing authorization for Kisqali for the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative  early breast cancer , at high risk of disease recurrence, including those with node-negative disease.Year to date, shares of Novartis have risen 16.1% compared with the industry’s growth of 20.6%.Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow cancer progression by inhibiting two proteins — cyclin-dependent kinase 4 and 6 .The positive CHMP decision for a broad population of patients diagnosed with HR+/HER2- EBC at high risk of recurrence is based on robust data from the late-stage NATALEE study.Following the CHMP’s positive recommendation, ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Tw87WEC1wh0JNb8.IBuFMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Tw87WEC1wh0JNb8.IBuFMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-gets-chmp-recommendation-kisqali-175100743.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BK4W5L77.USD","LU0211331839.USD","BK4532","CHMP","IE0004445239.USD","IE00BFTCPJ56.SGD","BK4585","IE00B1BXHZ80.USD","BAYRY","LU1057294990.SGD","IE0002141913.USD","LU0203202063.USD","LU0471298777.SGD","BK4581","LU0094547139.USD","IE00B2B36J28.USD","LU0820561818.USD","IE00BJJMRZ35.SGD","BK4533","BK4534","IE00B4R5TH58.HKD","LU0354030438.USD","LU0079474960.USD","EBC","LU0109391861.USD","LU0320765059.SGD","BK4578","EC","BK4516","IE00BJT1NW94.SGD","LU0466842654.USD","LU1035775433.USD","GB00BDT5M118.USD","LU0882574055.USD","BK4211","LU0114720955.EUR","LU0417517546.SGD","ET","IE00BJLML261.HKD","LU0289739699.SGD","LU0238689110.USD","LU0122379950.USD","LU0823416689.USD","LU1023059063.AUD","LU0096364046.USD","NVS","LU0882574139.USD","LLY","BK4561","LU0061475181.USD"],"gpt_icon":1},{"id":"2477651891","title":"NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B","url":"https://stock-news.laohu8.com/highlight/detail?id=2477651891","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477651891?lang=en_us&edition=fundamental","pubTime":"2024-10-21 23:52","pubTimestamp":1729525920,"startTime":"0","endTime":"0","summary":"Novo NordiskNVO announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years or older living with haemophilia A or B with inhibitors.Novo Nordisk’s Alhemo is a monoclonal antibody that blocks the TFPI, a protein that prevents blood clotting. By inhibiting TFPI, Alhemo promotes thrombin production, aiding blood clotting and stopping bleeding even in the absence/deficiency of other clotting factors. This enables Alhemo to promote clot formation even in the presence of inhibitors.The drug is already approved in Australia and Switzerland for treating adolescents and adults  with hemophilia A or B with inhibitors. NVO also markets Alhemo in Japan to treat the same patient population  and is used for routine prophylaxis to reduce or prevent bleeding episodes.Year to date, shares of Novo Nordisk have ga","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EaYjwqFOUx_QJeP7FQN8Aw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvos-alhemo-gets-positive-chmp-155200060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU1093756325.SGD","LU2065171402.SGD","BK4087","BK4139","LU2065171311.SGD","IE00BKVL7J92.USD","ALNY","FOLD","LU2065170008.USD","BK4585","IE00BZ1G4Q59.USD","BK4007","BK4156","ANIP","BK4588","LU1093756168.USD","LU2065169927.USD","NVO","LU0154236417.USD","BK4548","CHMP"],"gpt_icon":0},{"id":"2477837664","title":"BeiGene receives positive CHMP opinions for tevimbra in gastric cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2477837664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477837664?lang=en_us&edition=fundamental","pubTime":"2024-10-21 18:11","pubTimestamp":1729505469,"startTime":"0","endTime":"0","summary":"BeiGene (BGNE) announced that the Committee for Medicinal Products for Human Use – CHMP – of the European Medicines Agency issued positive opinions...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-receives-positive-chmp-opinions-for-tevimbra-in-gastric-cancers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-receives-positive-chmp-opinions-for-tevimbra-in-gastric-cancers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHMP","BK4087","BK4585","BK4504","BK4535","BK4139","BGNE","BK4548","BK4505","BK4588","BK4526"],"gpt_icon":0},{"id":"2477341398","title":"Ionis Pharmaceuticals announces CHMP recommends approval for Wainzua","url":"https://stock-news.laohu8.com/highlight/detail?id=2477341398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477341398?lang=en_us&edition=fundamental","pubTime":"2024-10-21 17:25","pubTimestamp":1729502737,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) announced that Ionis’ and AstraZeneca’s (AZN) Wainzua has been recommended for approval by the Committee for Medicinal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-announces-chmp-recommends-approval-for-wainzua?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-announces-chmp-recommends-approval-for-wainzua?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","IONS","LU1829250122.USD","AZN","LU2236285917.USD","BK4585","CHMP","LU2462157665.USD","BK4588","BK4087","LU0320765992.SGD","LU2456880835.USD","LU0889565916.HKD","LU0109394709.USD","LU2417539215.USD","BK4007","BK4139"],"gpt_icon":0},{"id":"2476295572","title":"European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2476295572","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476295572?lang=en_us&edition=fundamental","pubTime":"2024-10-19 01:37","pubTimestamp":1729273028,"startTime":"0","endTime":"0","summary":"On Friday,Novartis AG  announced that the European Medicines Agency’s  Committee for Medicinal Products for Human Use  has adopted a positive opinion for Kisqali .The CHMP recommended approval granting marketing authorization for Kisqali  for the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative  early breast cancer , at high risk of disease recurrence, including those with node-negative disease.Also Read: Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts.The CHMP decision is based on data from the Phase 3 NATALEE trial.In the trial, Kisqali plus endocrine therapy , compared to ET alone, lowered the risk of cancer recurrence by 25.1% in patients with stage II and III HR+/HER2- EBC.The data also demonstrated a consistent, clinically meaningful invasive disease-free survival  benefit across key pre-specified subgroups.Data from the pivotal trial also showed that the safety profile of Kisqali at the 400mg","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z6nxZ1dkWE6XVmXTuGaqJQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/c94a5df59fd910fbf3b86fb38cfa8793","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z6nxZ1dkWE6XVmXTuGaqJQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/c94a5df59fd910fbf3b86fb38cfa8793"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agencys-panel-supports-173708863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVS","EBC","EC","BK4581","ET","BK4201","IE00BFTCPJ56.SGD","MDCO","CHMP","LU0211331839.USD","BK4585","BK4590","IE0002141913.USD","BK4578","IE00BJJMRZ35.SGD","BK4087","IE00B2B36J28.USD","BK4211","BK4561","BK4532","BK4144","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4007","IE0009355771.USD","BK4588"],"gpt_icon":0},{"id":"2476936992","title":"Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2476936992","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476936992?lang=en_us&edition=fundamental","pubTime":"2024-10-19 01:21","pubTimestamp":1729272106,"startTime":"0","endTime":"0","summary":"On Friday, Novo Nordisk A/S  said that the European Medicines Agency’s  Committee for Medicinal Products for Human Use  adopted a positive opinion, recommending approval of Alhemo as the first once-daily subcutaneous prophylactic treatment for hemophilia patients aged 12 years or older, with A or B with inhibitors.Haemophilia is a rare bleeding disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding.Also Read: Novo Nordisk’s Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency.Alhemois an anti-tissue factor pathway inhibitor  monoclonal antibody that, if approved by the European Commission, will offer the first once-daily subcutaneous prophylactic treatment to people with hemophilia A or B with inhibitors.Alhemois designed to block a protein called TFPI in the body that stops blood from clotting.By blocking TFPI, Alhemoensures the production of thrombin, which helps to clot the blood and prevent bleeding,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/r.1Luvagss..uKx8hkgZ3Q--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/b6042f4416c5a6f246c8a544037010c5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/r.1Luvagss..uKx8hkgZ3Q--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/b6042f4416c5a6f246c8a544037010c5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/europe-drug-regulators-advising-panel-172146800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756168.USD","ABR","BK4110","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","TSVT","BK4585","BK4588","BK4139","LU1093756325.SGD","BK4007","BK4087","CHMP","BK4532","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2476238855","title":"PTC Therapeutics: CHMP Again Recommends Against Translarna Renewal","url":"https://stock-news.laohu8.com/highlight/detail?id=2476238855","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476238855?lang=en_us&edition=fundamental","pubTime":"2024-10-18 19:58","pubTimestamp":1729252680,"startTime":"0","endTime":"0","summary":"PTC Therapeutics has suffered another setback in its bid to keep its Duchenne muscular dystrophy drug Translarna on the market in Europe.PTC on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has once again recommended against renewal of the conditional marketing authorization for Translarna.The Warren, N.J., biopharmaceutical company said the European Commission will now review the CHMP's negative opinion, with a decision expected in about 67 days, adding that the drug will remain authorized in Europe pending the review.PTC initially won European conditional marketing authorization Translarna in 2014.The CHMP in September 2023 gave a negative opinion on the conversion of the conditional marketing authorization to full approval, as well as a negative opinion on a renewal of the  conditional green light. The panel had already maintained its negative opinion on the conditional renewal twice this year following re-examinations.Translarna accounte","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951198990.SGD","BK4139","LU2506952410.USD","LU1721428347.USD","LU0109394709.USD","BK4087","LU2362541513.USD","CHMP","BK4585","LU2362540622.SGD","LU1951200564.SGD","BK4554","LU2506952337.HKD","LU2477742899.HKD","LU0889565916.HKD","BK4023","PTCT","LU0320765992.SGD","LU1923623000.USD","PTC","BK4576","LU2362541273.HKD","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":126,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{}}}